Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…
Biotechnology
US, South San Francisco [HQ]
Investor Relations
Filing Reader · Print Documents · Transcripts
Could not find a transcript
Peer Group
Peers Analysis-
Sorry! None of TPST's peers has listed transcripts.
Upcoming Transcript Tools
- Full Text Search - Across All Transcripts
- Detail Speaker Profiles
- Non-US Transcripts